MALDI-ToF Mass Spectrometry for Hemoglobinopathy Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing hemoglobinopathies, such as sickle cell diseases and thalassemias, are often costly, time-consuming, and require multiple tests, making them inefficient for rapid screening and national screening policies.
Innovation Solution
The method involves using MALDI-ToF mass spectrometry to analyze whole blood or blood spot samples, which are lysed and diluted, and then subjected to citrate buffered formalin fixation, allowing for the detection of characteristic spectra patterns indicative of hemoglobinopathies by examining doubly charged ions in specific mass/charge ranges.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional diagnostic methods are used for hemoglobinopathies, then diagnostic accuracy is maintained, but the process becomes costly and time-consuming
Solution Approach 1:
The patent extracts and analyzes specific globin proteins (alpha and beta globins) from whole blood samples using mass spectrometry, rather than performing complete hemoglobin analysis. By focusing on the mass-to-charge ratio of individual globin chains, the method rapidly identifies mutations causing hemoglobinopathies without requiring time-consuming electrophoresis or chromatography steps, thus maintaining diagnostic accuracy while significantly reducing analysis time
Solution Approach 2:
The patent replaces conventional mechanical separation methods (electrophoresis, chromatography) with mass spectrometry detection. The mass spectrometer measures the mass-to-charge ratio of ionized globin proteins, providing rapid and accurate identification of hemoglobinopathies. This substitution eliminates the need for complex mechanical separation systems, reducing both time and cost while maintaining high diagnostic reliability
2Reliability
If multiple tests are performed for hemoglobinopathy diagnosis, then diagnostic completeness is improved, but process complexity increases
Solution Approach 1:
The patent employs a universal mass spectrometry-based method that can detect multiple types of hemoglobinopathies (sickle cell disease, thalassemia, other globin mutations) through a single testing procedure. The mass spectrometer analyzes the mass-to-charge ratio of globin proteins to identify various mutations simultaneously, eliminating the need for multiple specialized tests and reducing procedural complexity while maintaining diagnostic completeness
Solution Approach 2:
The patent changes the detection parameter from conventional electrophoretic mobility or chromatographic retention time to mass-to-charge ratio. This parameter change enables a single test to differentiate between various hemoglobinopathies based on their unique mass signatures, simplifying the diagnostic workflow while maintaining the ability to detect all major types of hemoglobin mutations
3Reliability
If conventional screening methods are used, then comprehensive analysis is achieved, but cost-effectiveness decreases
Solution Approach 1:
The patent utilizes disposable microfluidic devices or simple sample preparation materials (such as filter paper for dried blood spots) that can be mass-produced at low cost. These single-use components eliminate the need for expensive, complex instrumentation in point-of-care settings while maintaining screening accuracy through integrated mass spectrometry detection, significantly improving cost-effectiveness for population screening programs
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables rapid and cost-effective screening for hemoglobinopathies by identifying specific globin protein mutations, providing definitive diagnostic results with high sensitivity and specificity.
Implementation Method 1
subjected to matrix-assisted laser desorption/ionization spectrometry time of-flight mass spectrometry (MALDI-ToF MS)
Implementation Method 2
matrix-assisted laser desorption/ionization spectrometry time of-flight mass spectrometry (MALDI-ToF MS)
Implementation Method 3
Incubation with citrate buffered formalin followed by lysis
Data Source
Figure 1
Figure 2
Figure 3~4
AI summary
The method describes rapid screening of whole blood samples, pin prick and blood spot cards, subjected to MALDI – ToF Mass spectrometry. The spectra is generated and compared to those from normal healthy controls. Characteristic spectra are indicative of the presence of a hemoglobinopathy and the method can be used to screen/diagnose all sickle cell diseases, alpha and beta Thalassemias.